SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    K. Athanasakis, I. Petrakis, J. Kyriopoulos, ‘HepConomics’: cost-effective, indeed, but how can we pay for it?, Journal of Viral Hepatitis, 2015, 22, 6
  2. 2
    Jessica Cusato, Sarah Allegra, Amedeo De Nicolò, Lucio Boglione, Giovanna Fatiguso, Giuseppe Cariti, Alessia Ciancio, Antonina Smedile, Silvia Strona, Giulia Troshina, Mario Rizzetto, Giovanni Di Perri, Antonio D’Avolio, ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy, Biomedicine & Pharmacotherapy, 2015, 69, 63

    CrossRef

  3. 3
    Sandrine Cure, Ines Guerra, Calogero Cammà, Antonio Craxì, Giampiero Carosi, Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy, Journal of Medical Economics, 2015, 1

    CrossRef

  4. 4
    Paolo A. Cortesi, Luciana Scalone, Lorenzo G. Mantovani, Cost-effectiveness analysis of new drugs for chronic hepatitis C: The importance of updating utility values, Hepatology, 2015, 61, 3
  5. 5
    E Cariani, L Roli, G Missale, E Villa, C Ferrari, T Trenti, Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis, The Pharmacogenomics Journal, 2015,

    CrossRef

  6. 6
    Kazuaki Chayama, Fukiko Mitsui, C Nelson Hayes, Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection, Expert Review of Gastroenterology & Hepatology, 2015, 9, 1, 21

    CrossRef

  7. 7
    Jona T Stahmeyer, Siegbert Rossol, Christian Krauth, Outcomes, costs and cost–effectiveness of treating hepatitis C with direct acting antivirals, Journal of Comparative Effectiveness Research, 2015, 1

    CrossRef

  8. 8
    Salvatore Petta, Giuseppe Cabibbo, Calogero Cammà, Reply, Hepatology, 2015, 61, 3
  9. 9
    Alan HB Wu, Mandana Khalili, The birth and potential death ofIL28Bgenotyping for hepatitis C therapy, Personalized Medicine, 2015, 12, 2, 55

    CrossRef

  10. 10
    S. E. Congly, S. S. Lee, Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?, Alimentary Pharmacology & Therapeutics, 2014, 40, 8
  11. 11
    Rodolfo Sacco, Gennaro Gadaleta-Caldarola, Giovanni Galati, Giuseppe Lombardi, GianCarlo Mazza, Giuseppe Cabibbo, European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?, Future Oncology, 2014, 10, 10, 1719

    CrossRef

  12. 12
    Alessio Strazzulla, Chiara Costa, Vincenzo Pisani, Vincenzo De Maria, Francesca Giancotti, Sebastiano Di Salvo, Saverio Parisi, Monica Basso, Marzia Franzetti, Nadia Marascio, Maria Liberto, Giorgio Barreca, Angelo Lamberti, Emilia Zicca, Maria Postorino, Giovanni Matera, Alfredo Focà, Carlo Torti, Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals, BMC Infectious Diseases, 2014, 14, Suppl 5, S3

    CrossRef

  13. 13
    Sofosbuvir cost effective in HCV G1 − if the price is right, PharmacoEconomics & Outcomes News, 2014, 701, 1, 6

    CrossRef

  14. 14
    G. M. Abraham, L. M. Spooner, Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks, Clinical Infectious Diseases, 2014, 59, 3, 411

    CrossRef

  15. 15
    Francesco Azzaroli, Marco Montagnani, Alberto Porro, Domenico Fiorillo, Giuseppe Mazzella, The future of dual therapy for hepatitis C virus, Future Virology, 2014, 9, 10, 905

    CrossRef

  16. 16
    Zobair Younossi, Linda Henry, The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C, Digestive and Liver Disease, 2014, 46, S186

    CrossRef

  17. 17
    Fabio Conti, Giovanni Vitale, Pietro Andreone, Treating hepatitis C in the elderly: the future is near?, Expert Opinion on Pharmacotherapy, 2014, 15, 14, 2019

    CrossRef

  18. 18
    Anil C. Anand, Treatment of chronic hepatitis C: What is new?, Apollo Medicine, 2014, 11, 2, 93

    CrossRef

  19. 19
    Zohreh Movahedi Smith, Keith Brussman, Abdul Nadir, Treatment of Hepatitis C With the Earliest Protease Inhibitor–Based Therapy, Mayo Clinic Proceedings, 2014, 89, 9, 1319

    CrossRef